Abstract
Statin monotherapy is the mainstay of low-density lipoprotein cholesterol (LDL-C) management for high cardiovascular risk patients in Portugal; however, several therapeutic options are available and predicted to have different clinical and economic impacts. The aim of this study was to evaluate the cost-effectiveness of adding ezetimibe 10 mg (EZ10) to atorvastatin 10 or 20 mg (A10/20) vs switching to rosuvastatin 10 or 20 mg (R10/20) in Portuguese patients with coronary heart disease (CHD) and/or diabetes who are currently above the LDL-C goal. A Markov model was used to describe CHD disease progression and the lifetime costs and utilities associated with each disease state were used to estimate the gains in life-years and quality-adjusted life-years (QALYs), as well as the incremental cost-effectiveness ratio (ICER), of the two treatment regimens. Model inputs, such as age, gender, and prevalence of cardiovascular risk factors of the dyslipidemic Portuguese patients were obtained from the Portuguese cohort of the Dyslipidemia International Study (DYSIS). The efficacy of each treatment regimen, the cost of drugs and of treating CHD events, and the utilities for each disease state were derived from published sources. The estima...Continue Reading
References
Jan 29, 2000·American Heart Journal·R B D'AgostinoS C Hartz
Jan 7, 2003·American Heart Journal·Kathryn A MelsopMark A Hlatky
Jan 16, 2004·BMJ : British Medical Journal·Steve GoodacreFrancis Morris
Apr 13, 2004·American Heart Journal·Herbert SchusterUNKNOWN Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group
Sep 25, 2004·American Heart Journal·Evan SteinUNKNOWN Ezetimibe Study Group
Jan 27, 2005·PharmacoEconomics·John R CookMichael Drummond
Jan 27, 2005·PharmacoEconomics·John R CookXavier Badia
Mar 24, 2006·Pharmacotherapy·Michael F BullanoVincent J Willey
Apr 29, 2006·American Heart Journal·Christie M BallantyneJoel S Raichlen
Jan 25, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael F BullanoVincent J Willey
Sep 23, 2008·Clinical Therapeutics·Roberta AraJim Chilcott
Dec 9, 2008·American Heart Journal·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Nov 10, 2009·Current Medical Research and Opinion·Erkki J O SoiniLeo Niskanen
May 22, 2010·International Journal of Clinical Practice·T McCormackUNKNOWN IN-PRACTICE study
Jun 22, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John RecklessPhilippe Brudi
Sep 21, 2010·DNA and Cell Biology·Jun WuHuai-Qing Chen
Jun 15, 2011·Lancet·Colin BaigentUNKNOWN SHARP Investigators
Jun 15, 2011·International Journal of Computer Assisted Radiology and Surgery·Cristian A LinteTerry M Peters
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Oct 25, 2011·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·F van NootenX H Hu
Citations
Jul 3, 2015·Expert Opinion on Drug Safety·Nazik Elmalaika HusainMohamed H Ahmed
Jun 1, 2017·Journal of Medical Economics·Jesse D OrtendahlMichael S Broder
Dec 5, 2018·Health Technology Assessment : HTA·Alison AvenellMarijn de Bruin
Feb 2, 2019·International Journal of Obesity : Journal of the International Association for the Study of Obesity·Lise RetatPaul Aveyard
Jan 18, 2019·Experimental and Therapeutic Medicine·Gang Ma, Shuting Bi
Jun 6, 2021·International Journal of Obesity : Journal of the International Association for the Study of Obesity·D BoyersUNKNOWN REBALANCE team